Examkin

Question

Difficulty: MediumPsychopharmacology and Psychological Therapies

A psychiatric hospital is updating its standardized clinical pathways for medication safety. Match each psychotropic medication with the most appropriate baseline or ongoing screening modality required to monitor its specific adverse effect profile.

  • ClozapineAbsolute neutrophil count
  • LithiumThyroid-stimulating hormone
  • ValproateSerum transaminases
  • ZiprasidoneElectrocardiogram

Answer

Clozapine pairs with absolute neutrophil count; Lithium pairs with thyroid-stimulating hormone; Valproate pairs with serum transaminases; and Ziprasidone pairs with electrocardiogram.
Each psychotropic medication listed requires a distinct monitoring parameter based on its unique side effect profile: clozapine requires absolute neutrophil count for agranulocytosis, lithium requires thyroid-stimulating hormone for hypothyroidism, valproate requires serum transaminases for hepatotoxicity, and ziprasidone requires an electrocardiogram for QTc prolongation.

Step-by-Step Solution

1
Identify the primary dose-limiting or life-threatening adverse effect associated with each psychotropic medication.
Clozapine can cause agranulocytosis, lithium causes hypothyroidism, valproate causes hepatotoxicity, and ziprasidone causes QTc prolongation.
Understanding the distinct toxicity profile is necessary to select the correct screening test.
2
Correlate the identified adverse effect with the corresponding laboratory test or diagnostic study.
Agranulocytosis requires absolute neutrophil count, hypothyroidism requires thyroid-stimulating hormone, hepatotoxicity requires transaminases, and QTc prolongation requires an electrocardiogram.
Clinical guidelines mandate specific surveillance testing to prevent severe morbidity from these agents.

Key Concept

Routine safety monitoring for psychotropic medications is dictated by their distinct adverse effect profiles.
Rate this question

Topics

Psychopharmacology and Psychological Therapies

More questions from this topic